AFNI OKTARIA SARINING WULAN, 0303911101 (2013) PERJANJIAN KARTEL ANTAR PERUSAHAAN FARMASI DENGAN DOKTER (Studi Kasus Putusan KPPU-RI Nomor 17/KPPU-I/2010 tertanggal 27 September 2010). Skripsi thesis, UNIVERSITAS AIRLANGGA.

Preview	Text (ABSTRAK) gdlhub-gdl-s1-2013-wulanafnio-24777-6.abstr-t.pdf Download (216kB) | Preview
	Text (FULLTEXT) AFNI OKTARIA SARINING.pdf Restricted to Registered users only Download (734kB) | Request a copy

Abstract

Rising drug prices that have content on the market Amlodipine Besylate cause unrest in the community and for that competition watchdog commission examining the release of the alleged cartel practices have occurred that lead to monopoly and unfair competition against the case filed by two formulation of the problem. Based on the description, it will be assessed on: (a) Is the Party in this PT. Pfizer Indonesia, PT. Dexa Medica, Pfizer Inc., Pfizer Overseas LLC., Pfizer Global Trading (co Pfizer), and Pfizer Corporation Panama, has entered into a cartel that lead to monopolistic practices and unfair business competition, (b) Is the punishment for physicians who conduct transactions with drug manufacturers that impact the occurrence of excessive drug pricing anomalies. This study aimed to analyze the concept of cartel agreements in the legal relationship between the Party that leads to monopolistic practices and unfair business competition and analyze their penalties for doctors who enter into transactions with drug manufacturers that impact the high price of drugs is excessive. The approach in this study is the approach to legislation, conceptual approach, and the approach to the case. The Reported in this PT. Pfizer Indonesia, PT. Dexa Medica, Pfizer Inc., Pfizer Overseas LLC., Pfizer Global Trading (co Pfizer), and Pfizer Corporation Panama, proved to have done cartel agreements that lead to monopolistic practices in unfair competition. Reported prove the cartel Agreement on relations between the parties established through Supply Agreement led to the coordination and regulation of production and sales between Dexa Medica group effort with Pfizer in this case the overseas-Pfizer Pfizer Indonesia. Penalties for doctors involved in the conspiracy with drug manufacturers sanctions contained in the Code of Medical Ethics and Medical Practice Act and may also be liable under Article 22, Article 23 and Article 24 of Law No. 5/1999 subject to administrative sanctions and criminal sanctions in the form of principal and additional criminal offense, as in Article 48 paragraph (2) and (3) of Law No. 5/1999.

Actions (login required)

View Item